Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Managing chronic adult hypophosphatasia (HPP) requires a coordinated, multidisciplinary approach, and several factors determine which steps make sense for you. See below to understand more about how treatment decisions are made.
Enzyme replacement therapy with asfotase alfa is the only disease-targeted treatment available, though eligibility in adults often depends on documented skeletal disease, fractures, or significant functional impairment rather than symptoms alone. Supportive care remains central and typically includes physical therapy to preserve mobility, NSAIDs or other analgesics for bone and joint pain, dental monitoring for tooth loss and periodontal disease, and vitamin B6 supplementation in select cases. Critically, bisphosphonates and high-dose vitamin D or phosphate supplements should generally be avoided, as they can worsen HPP outcomes, and confirming the diagnosis through low alkaline phosphatase levels, elevated substrate markers, and ALPL genetic testing is essential before any treatment plan begins.
Because adult HPP is frequently misdiagnosed as osteoporosis, fibromyalgia, or osteoarthritis, and because the details of your fracture history, pain pattern, and lab results shape which next steps apply, reviewing the full information below matters. If persistent bone pain, unexplained fractures, dental problems, or muscle weakness sound familiar, a free, instant online symptom check can help you organize your symptoms and understand how to discuss them with your clinician.
Last reviewed for medical accuracy: 08/18/2026
Chronic adult hypophosphatasia (HPP) is a rare metabolic bone disorder caused by low activity of the enzyme alkaline phosphatase. This can lead to stress fractures, muscle weakness, dental issues and chronic pain. If you’ve been diagnosed with HPP or suspect you may have it, here are practical, evidence-based steps to take control of your health and quality of life.
Before moving forward, make sure your diagnosis and disease status are up to date.
If you’re still gathering information, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you organize your concerns and discuss them with your specialist (https://ubiehealth.com/).
Asfotase alfa (Strensiq) is the first targeted treatment for HPP. While initially approved for pediatric-onset disease, it has shown benefits in adults with childhood-onset HPP.
Key points about ERT:
Speak with an endocrinologist or metabolic bone specialist to determine if you’re a candidate for asfotase alfa, understand insurance coverage and set realistic expectations.
Chronic pain is one of the most disabling features of adult HPP. An individualized pain plan can improve function and mood.
Combine medications with non-drug approaches like heat therapy, gentle massage or TENS (transcutaneous electrical nerve stimulation).
Building strength and balance helps reduce fracture risk and improves mobility.
Work with a physical therapist experienced in metabolic bone disease to progress safely.
Dental complications—early tooth loss and periodontal issues—are common in adult HPP.
Timely attention to dental concerns prevents infections and preserves function.
While there’s no special HPP diet, certain habits support bone and muscle health.
Consult a dietitian if you have concerns about nutrient intake or weight management.
Some drugs may worsen HPP or increase complications:
Always review new prescriptions with your metabolic bone specialist or pharmacist.
Adult HPP can involve multiple systems. Regular check-ins help catch issues early.
Keep a symptom diary and bring it to your appointments to track progress.
Ongoing studies may offer access to novel therapies or combinations.
Participation can advance understanding and potentially improve your outcomes.
Given its complexity, adult HPP benefits from a team approach:
Regular communication among your providers ensures cohesive care.
Managing chronic adult hypophosphatasia requires a proactive plan that combines targeted therapy, symptom relief, lifestyle support and vigilant monitoring. You’re not alone—your healthcare team, support networks and new tools like the “free, online symptom check, using the doctor approved Ubie Symptom Checker” can help you stay on top of your health journey (https://ubiehealth.com/).
If you experience any life-threatening or serious symptoms—such as severe pain, breathing difficulty, sudden fractures or profound weakness—speak to a doctor right away. Even routine questions about your treatment or changes in symptoms deserve professional guidance. Taking these evidence-based steps can help you live more comfortably and maintain your best possible bone health.
(References)
* Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. PMID: 26893260.
* Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25. PMID: 28888853.
* Briot K, Roux C. Adult hypophosphatasia. Arch Pediatr. 2017 May;24(5S2):5S71-5S73. doi: 10.1016/S0929-693X(18)30018-6. PMID: 29405936.
* Vimalraj S. Alkaline phosphatase: Structure, expression and its function in bone mineralization. Gene. 2020 Sep 5;754:144855. doi: 10.1016/j.gene.2020.144855. Epub 2020 Jun 6. PMID: 32522695.
* Fenn JS, Lorde N, Ward JM, Borovickova I. Hypophosphatasia. J Clin Pathol. 2021 Oct;74(10):635-640. doi: 10.1136/jclinpath-2021-207426. Epub 2021 Apr 30. PMID: 33931563.
* Tournis S, Yavropoulou MP, Polyzos SA, Doulgeraki A. Hypophosphatasia. J Clin Med. 2021 Dec 1;10(23). doi: 10.3390/jcm10235676. Epub 2021 Dec 1. PMID: 34884378; PMCID: PMC8658462.
* Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.
* Reis FS, Lazaretti-Castro M. Hypophosphatasia: from birth to adulthood. Arch Endocrinol Metab. 2023 May 25;67(5):e000626. doi: 10.20945/2359-3997000000626. PMID: 37249457; PMCID: PMC10665056.
* Khan AA, Brandi ML, Rush ET, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Simmons JH, Starling SR, Ward LM, Yao L, Brignardello-Petersen R, Lewiecki EM. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024 Mar;35(3):431-438. doi: 10.1007/s00198-023-06844-1. Epub 2023 Nov 20. PMID: 37982857; PMCID: PMC10866785.
* Seefried L, Genest F, Hofmann C, Brandi ML, Rush E. Diagnosis and Treatment of Hypophosphatasia. Calcif Tissue Int. 2025 Mar 6;116(1):46. doi: 10.1007/s00223-025-01356-y. Epub 2025 Mar 6. PMID: 40047955; PMCID: PMC11885340.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.